Nanogam (Human Normal Immunoglobulin)

Nanogam is used in the management of immune‑deficient conditions where IgG replacement is required.

• Primary immunodeficiency diseases: supplies pooled IgG to reduce the frequency and severity of infections.
• Secondary immunodeficiency (e.g., chemotherapy, HIV): provides passive antibodies that support immune function during treatment.
• Prevention of infections in immunocompromised patients: lowers the risk of bacterial and viral infections by enhancing humoral immunity.

• Human Normal Immunoglobulin in Nanogam consists of pooled IgG antibodies that bind to a broad range of pathogens, neutralizing viruses, bacteria, and toxins. The antibodies also interact with Fc receptors on immune cells, modulating complement activation and cytokine release, thereby restoring humoral immunity and helping to prevent infection in deficient patients.

Nanogam may cause a range of adverse reactions, most of which are related to the infusion process or the immunoglobulin content.

Common Side Effects

• Headache: mild to moderate pain often occurring during or after infusion.
• Fever and chills: transient rise in body temperature and shivering.
• Nausea: occasional upset stomach during administration.
• Fatigue: feeling of tiredness post‑infusion.
• Infusion‑related reactions: flushing, erythema, or mild hypotension.
• Muscle aches: soreness in limbs after treatment.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Thromboembolic events: blood clots that may affect veins or arteries.
• Renal dysfunction: impaired kidney function, especially with high‑dose regimens.
• Aseptic meningitis: inflammation of the meninges without infection.
• Hemolysis: destruction of red blood cells leading to anemia.
• Severe thrombocytopenia: markedly low platelet count increasing bleeding risk.

Before initiating Nanogam therapy, clinicians should evaluate patient history and monitor for potential complications.

• Assess baseline IgG levels: determine need for replacement therapy.
• Monitor for infusion reactions: observe vital signs during and after administration.
• Adjust infusion rate in renal impairment: slower rates reduce renal stress.
• Avoid in patients with known IgA deficiency and anti‑IgA antibodies: risk of severe anaphylaxis.
• Use caution during pregnancy: safety data are limited, weigh benefits against potential risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nanogam can interact with other agents that affect immune function or hemostasis.

Major Interactions (Avoid)

• Live vaccines: concurrent use may diminish vaccine efficacy and increase infection risk.
• Other immunoglobulin products: combined therapy can lead to IgG overload and increased adverse events.

Moderate Interactions (Monitor Closely)

• Corticosteroids: may augment infection susceptibility, requiring closer monitoring.
• Anticoagulants: immunoglobulin can affect coagulation parameters, potentially altering bleeding risk.
• ACE inhibitors: may increase incidence of hypotensive episodes during infusion.
• Immunosuppressants: combined effect on immune system warrants regular assessment of infection markers.